New Edition of Definitive (Two-Volume) Resource in Stem Cells Released Today

MARLBOROUGH, Mass.--(BUSINESS WIRE)--

Advanced Cell Technology, Inc. (ACT; OTCBB: ACTC), a leader in the field of regenerative medicine, announced today that its chief scientific officer, Robert Lanza, M.D. and Anthony Atala, M.D., W.H. Boyce Professor and Director of the Wake Forest Institute for Regenerative Medicine, have released the second edition of Handbook of Stem Cells (Academic Press/Elsevier), the widely-recognized definitive resource in the field of stem cells. It includes a Forward by Professor Sir Martin Evans, Ph.D., FRS, co-winner of the Nobel Prize for Physiology or Medicine in 2007. Sir Martin is credited with discovering embryonic stem cells and is considered one of the chief architects of the field of stem cell research. The two-volume set also includes contributions from dozens of stem cell pioneers, including James Thomson, Shinya Yamanaka, Doug Melton, Janet Rossant, and Robert Langer (a member of ACTs board of directors), among others, as well as patient advocate Mary Tyler Moore.

Handbook of Stem Cells, Second Edition follows a very successful edition published in 2004. The first edition was the first comprehensive body of work dedicated entirely to the stem cell field. The two-volume set quickly became the most relevant textbook in the stem cell arena. Now, several years later, major advances have occurred, with entirely new classes of stem cells being described. The description of induced pluripotent cells in the last few years brought many more avenues of research and discovery. In 2012, the first paper reporting results of two patients treated with human embryonic stem cells was published by ACT and its collaborators. It might seem that we have waited too long to finally see pluripotent stem cells in the clinic. However, this has been accomplished with incredible speed when it is considered that hESCs were first isolated just 14 years ago. Handbook of Stem Cells integrates this exciting area, combining in two volumes the requisites for a general understanding of both adult and embryonic stem cells. Organized in two volumes, Pluripotent Stem Cells and Adult & Fetal Stem Cells, this work contains contributions from the world's experts in stem cell research to provide a description of the tools, methods, and experimental protocols needed to study and characterize stem cells and progenitor populations as well as a the latest information of what is known about each specific organ system.

The Handbook of Stem Cells, edited by Robert Lanza and colleagues, is an ambitious new text that achieves extraordinary completeness and inclusiveness, wrote Steve Goldman of University of Rochester Medical Center in NATURE CELL BIOLOGY about the first edition. [...] the editors have succeeded in putting together a reference that is broad enough in scope, but sufficiently detailed and rigorous, to be of real interest to both new and seasoned investigators in the field [...] In providing this treatise, which covers the history, biology, methods and applications of stem cells, the editors and authors have succeeded in establishing a conceptual framework and a common language for the field. In so doing, they have ensured that this two-volume set will serve as a benchmark reference in stem cell biology for years to come.

Writing about the first edition in the Times Higher Education Supplement, Ian Wilmut added, These books make an invaluable contribution to the education of researchers and clinicians both of the present day and of the future. They should be available in libraries of all biology and medical schools as well as those of companies and research institutions.

About Advanced Cell Technology, Inc.

Advanced Cell Technology, Inc., is a biotechnology company applying cellular technology in the field of regenerative medicine. For more information, visit http://www.advancedcell.com.

Forward-Looking Statements

Statements in this news release regarding future financial and operating results, future growth in research and development programs, potential applications of our technology, opportunities for the company and any other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Any statements that are not statements of historical fact (including statements containing the words will, believes, plans, anticipates, expects, estimates, and similar expressions) should also be considered to be forward-looking statements. There are a number of important factors that could cause actual results or events to differ materially from those indicated by such forward-looking statements, including: limited operating history, need for future capital, risks inherent in the development and commercialization of potential products, protection of our intellectual property, and economic conditions generally. Additional information on potential factors that could affect our results and other risks and uncertainties are detailed from time to time in the companys periodic reports, including the report on Form 10-K for the year ended December 31, 2011. Forward-looking statements are based on the beliefs, opinions, and expectations of the companys management at the time they are made, and the company does not assume any obligation to update its forward-looking statements if those beliefs, opinions, expectations, or other circumstances should change. Forward-looking statements are based on the beliefs, opinions, and expectations of the companys management at the time they are made, and the company does not assume any obligation to update its forward-looking statements if those beliefs, opinions, expectations, or other circumstances should change. There can be no assurance that the Companys clinical trials will be successful.

Read more:
New Edition of Definitive (Two-Volume) Resource in Stem Cells Released Today